{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-308316","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2022-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.519957+00:00","generated_at":"2026-06-21T02:34:52.804929+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Aeglea amends bylaws for universal proxy rules, DGCL changes, and meeting procedures","bullets":["Board adopted amended bylaws effective December 15, 2022.","Revised advance notice provisions: requires additional disclosures, limits nominees to directors up for election, and mandates nominee interviews.","Added compliance measures for SEC Rule 14a-19 universal proxy, including certification and notice requirements.","Updated adjournment procedures and stockholder meeting conduct; added emergency bylaw for quorum failure.","Conformed notice provisions to DGCL electronic transmission amendments."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-308316","json":"https://secwatch.observer/filing/0001193125-22-308316.json","markdown":"https://secwatch.observer/filing/0001193125-22-308316.md","text":"https://secwatch.observer/filing/0001193125-22-308316.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000119312522308316/0001193125-22-308316-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000119312522308316/d414065d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T02:34:52.804929+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ab71ddf9ca23aa8dbbd51f35b61ad18b0e8c5102","claim":"Spyre Therapeutics, Inc.: Amended and restated bylaws to conform to DGCL amendments and universal proxy rules, including revisions to stockholder meeting procedures, advance notice provisions, and emergency bylaws (effective 2022-12-15).","evidence_excerpt":"On December 15, 2022, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “ DGCL ”), and a periodic review of the bylaws of Aeglea Biotherapeutics, Inc. (the “ Company ”), the Company’s board of directors (the “ Board ”) approved and adopted the Company’s amended and restated bylaws (the “ Amended and Restated Bylaws ”), which became immediately effective.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000119312522308316/0001193125-22-308316-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2022-12-15"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}